Cannabis as a Source of Approved Drugs: A New Look at an Old Problem

被引:11
作者
Gabarin, Adi [1 ]
Yarmolinsky, Ludmila [1 ]
Budovsky, Arie [2 ]
Khalfin, Boris [1 ]
Ben-Shabat, Shimon [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, IL-84105 Beer Sheva, Israel
[2] Barzilai Univ, Res & Dev Author, Med Ctr, IL-7830604 Ashqelon, Israel
来源
MOLECULES | 2023年 / 28卷 / 23期
关键词
cannabis; drugs; cannabidiol; tetrahydrocannabinol; HIGH-POTENCY CANNABIS; ENDOCANNABINOID SYSTEM; SYNTHETIC CANNABINOIDS; MARIJUANA; HEALTH; PHARMACOLOGY; DEMENTIA; SYNERGY; DISEASE; BRAIN;
D O I
10.3390/molecules28237686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cannabis plants have been used in medicine since ancient times. They are well known for their anti-diabetic, anti-inflammatory, neuroprotective, anti-cancer, anti-oxidative, anti-microbial, anti-viral, and anti-fungal activities. A growing body of evidence indicates that targeting the endocannabinoid system and various other receptors with cannabinoid compounds holds great promise for addressing multiple medical conditions. There are two distinct avenues in the development of cannabinoid-based drugs. The first involves creating treatments directly based on the components of the cannabis plant. The second involves a singular molecule strategy, in which specific phytocannabinoids or newly discovered cannabinoids with therapeutic promise are pinpointed and synthesized for future pharmaceutical development and validation. Although the therapeutic potential of cannabis is enormous, few cannabis-related approved drugs exist, and this avenue warrants further investigation. With this in mind, we review here the medicinal properties of cannabis, its phytochemicals, approved drugs of natural and synthetic origin, pitfalls on the way to the widespread clinical use of cannabis, and additional applications of cannabis-related products.
引用
收藏
页数:21
相关论文
共 213 条
  • [61] Eagleston Lauren R M, 2018, Dermatol Online J, V24
  • [62] ElSohly M.A., 2023, Critical Issues in Alcohol and Drugs of Abuse Testing, P273
  • [63] ElSohly MA, 2017, PROG CHEM ORG NAT PR, V103, P1, DOI 10.1007/978-3-319-45541-9_1
  • [64] European Monitoring Centre for Drugs and Drug Addiction, 2020, LOW THC CANN PROD EU, P19, DOI [10.2810/69625, DOI 10.2810/69625]
  • [65] Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems
    Fantegrossi, William E.
    Wilson, Catheryn D.
    Berquist, Michael D.
    [J]. DRUG METABOLISM REVIEWS, 2018, 50 (01) : 65 - 73
  • [66] The Seed of Industrial Hemp (Cannabis sativaL.): Nutritional Quality and Potential Functionality for Human Health and Nutrition
    Farinon, Barbara
    Molinari, Romina
    Costantini, Lara
    Merendino, Nicolo
    [J]. NUTRIENTS, 2020, 12 (07) : 1 - 60
  • [67] Comparing microfluidics and ultrasonication as formulation methods for developing hempseed oil nanoemulsions for oral delivery applications
    Fathordoobady, Farahnaz
    Sannikova, Natalia
    Guo, Yigong
    Singh, Anika
    Kitts, David D.
    Pratap-Singh, Anubhav
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [68] Ultralow Doses of Cannabinoid Drugs Protect the Mouse Brain From Inflammation-Induced Cognitive Damage
    Fishbein-Kaminietsky, Miriam
    Gafni, Mikhal
    Sarne, Yosef
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2014, 92 (12) : 1669 - 1677
  • [69] Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
    Franco, Valentina
    Perucca, Emilio
    [J]. DRUGS, 2019, 79 (13) : 1435 - 1454
  • [70] Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA
    Gamage, Thomas F.
    Farquhar, Charlotte E.
    Lefever, Timothy W.
    Marusich, Julie A.
    Kevin, Richard C.
    McGregor, Iain S.
    Wiley, Jenny L.
    Thomas, Brian F.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 365 (02) : 437 - 446